Globus Medical (GMED) Stock Price, News & Analysis

Company Overview

Globus Medical, Inc. (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room. The ExcelsiusGPS® robotic guidance system, for example, integrates real-time imaging with robotic arm technology to enable surgeons to perform complex procedures with greater accuracy. The company also offers an array of trauma and orthopaedic solutions, such as bone graft substitutes and joint reconstruction implants, to address a broad spectrum of musculoskeletal conditions.

Globus Medical serves surgeons and patients across North America, Europe, Asia, Latin America and the Middle East through a combination of direct sales and distribution partnerships. Under the leadership of founder and Executive Chairman David C. Paul and President and Chief Executive Officer Glenn J. Shapiro, the company has built a global commercial infrastructure and invested in research and development to drive innovation. Its commitment to surgical education and customer support further reinforces its position in the competitive medical device landscape.

Key Stats

• Today's Range: $81.80 to $83.53
• 50-Day Range: $75.48 to $88.48
• 52-Week Range: $54.15 to $101.40
• Volume: 1.06 million shs
• Average Volume: 1.37 million shs
• Market Capitalization: $11.15 billion
• P/E Ratio: 21.24
• Dividend Yield: N/A
• Price Target: $101.77
• Consensus Rating: Moderate Buy

Globus Medical Stock Analysis - MarketRank™

Globus Medical scored higher than 91% of companies evaluated by MarketBeat, and ranked 47th out of 913 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.2 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Globus Medical has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 3 strong buy ratings, 9 buy ratings, 5 hold ratings, and no sell ratings.

Upside Potential

Globus Medical has a consensus price target of $101.77, representing about 22.6% upside from its current price of $83.03.

Amount of Analyst Coverage

Globus Medical has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 8.02%

Earnings Growth

Earnings for Globus Medical are expected to grow by 8.02% in the coming year, from $4.99 to $5.39 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Globus Medical is 21.24, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 45.16.

Price to Earnings Ratio vs. Sector

The P/E ratio of Globus Medical is 21.24, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 273.16.

Price to Earnings Growth Ratio

Globus Medical has a PEG Ratio of 1.34. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Globus Medical has a P/B Ratio of 2.34. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

6.21% of the float of Globus Medical has been sold short.

Short Interest Ratio / Days to Cover

Globus Medical has a short interest ratio ("days to cover") of 3.95, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Globus Medical has recently decreased by 1.22%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Globus Medical does not currently pay a dividend.

Dividend Growth

Globus Medical does not have a long track record of dividend growth.

News and Social Media

• Score: 3.7 / 5
• News Sentiment: 0.93

News Sentiment

Globus Medical has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 15 news articles for Globus Medical this week, compared to 6 articles on an average week.

Search Interest

13 people have searched for GMED on MarketBeat in the last 30 days. This is an increase of 63% compared to the previous 30 days.

MarketBeat Follows

5 people have added Globus Medical to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days.

Company Ownership

• Score: 2.1 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Globus Medical insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,195,000.00 in company stock.

Percentage Held by Insiders

18.38% of the stock of Globus Medical is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

95.16% of the stock of Globus Medical is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/06/2026
• Today: 8/30/2026
• Next Earnings (Estimated): 11/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: NYSE:GMED
• CIK: 1237831
• Web: www.globusmedical.com
• Phone: (610) 930-1800
• Fax: 610-930-2042
• Employees: 6,000
• Year Founded: 2003

Price Target and Rating

• Average Price Target for Globus Medical: $101.77
• High Price Target: $123.00
• Low Price Target: $80.00
• Potential Upside/Downside: +22.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.88
• Research Coverage: 17 Analysts

Profitability

• EPS (Trailing Twelve Months): $3.91
• Trailing P/E Ratio: 21.24
• Forward P/E Ratio: 16.64
• P/E Growth: 1.34
• Net Income: $537.87 million
• Net Margins: 17.02%
• Pretax Margin: 20.99%
• Return on Equity: 14.57%
• Return on Assets: 12.62%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.62
• Quick Ratio: 2.93

Sales & Book Value

• Annual Sales: $2.94 billion
• Price / Sales: 3.79
• Cash Flow: $6.29 per share
• Price / Cash Flow: 13.21
• Book Value: $35.52 per share
• Price / Book: 2.34

Miscellaneous

• Outstanding Shares: 134,260,000
• Free Float: 109,585,000
• Market Cap: $11.15 billion
• Optionable: Optionable
• Beta: 0.95